Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

What Was Tested

This clinical trial, phase iii paper looks at Abaloparatide in the context of osteoporosis and bone density.

The objective of this study was to evaluate the early effects of abaloparatide on indices of bone formation and to assess the effect of abaloparatide on modeling-based formation (MBF), remodeling-based formation (RBF), and overflow MBF (oMBF) in transiliac bone biopsies.

Why It Was Studied

Subjects received double fluorochrome labels before treatment and before biopsy collection at 3 months.

Who Took Part

The study group was 23 women.

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as open-label.

Being open-label, the Abaloparatide study did not mask who received what.

Change in dynamic histomorphometry indices in four bone envelopes were assessed.

What Was Measured

The subject headings attached to it are Bone Density, Osteogenesis, Osteoporosis, Osteoporosis, Postmenopausal, Parathyroid Hormone-Related Protein and Postmenopause.

The authors tagged it with the keywords ANABOLICS, BONE HISTOMORPHOMETRY, BONE MODELING AND REMODELING and CLINICAL TRIAL.

What This Means in Plain Language

The paper is an open-label study of Abaloparatide in 23 women in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Abaloparatide compound page, Osteoporosis and bone density research.